Adrian Rabin
Lawyers
Filters
Denali Therapeutics $400 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Solid Biosciences $200 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
Williams $325 million acquisition of Rimrock gathering and processing system
We advised Williams on the transaction
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Uranium Energy $300 million at-the-market offering
The shares are listed on NYSE American
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market